ijms-logo

Journal Browser

Journal Browser

Cancer Genomics, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: closed (30 October 2025) | Viewed by 651

Special Issue Editors


E-Mail Website
Guest Editor
Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Concepcin, Chile
Interests: RNA biology; cancer functional genomics; precision medicine; molecular diagnostics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
Laboratory of Cellular and Molecular Oncology, Department of Basic and Clinical Oncology, Faculty of Medicine, University de Chile, Santiago 8380453, Chile
Interests: epithelial–mesenchymal transition; cancer stem cell; prostate cancer; colon cancer; breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the development and progression of cancer, neoplastic cells acquire a series of genetic changes that result in drastic modifications both in how the cell responds to its environment and in the cell dynamics itself. Advancements in genomic technologies and next-generation sequencing have produced a wealth of information and provided substantial insights into the pathogenesis of diseases. Especially in cancer, these tools have been exceptionally useful for identifying novel signal transduction pathways, with a great potential for the discovery of new biomarkers and therapeutic targets. However, the translation of these findings into a breakthrough in the understanding of cancer biology and the care of cancer patients remains a major challenge.

This Special Issue highlights novel findings in cancer genomics arising from the combined use of computational tools, high-throughput sequencing technology, bioinformatics, cell biology and translational research to understand cancer biology, from genomics to cell signaling and from disease models to actual patients. Translational efforts to make the knowledge of cellular and molecular biology of cancer useful for patients with cancer, and research performed in understudied specific cancer patients, are of special interest.

Dr. Ricardo Armisén
Dr. Hector R. Contreras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision oncology
  • cancer genomics
  • personalized medicine
  • mutagenesis
  • molecular epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 5241 KB  
Review
Microbiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation
by Sungwon Jung
Int. J. Mol. Sci. 2026, 27(4), 2068; https://doi.org/10.3390/ijms27042068 - 23 Feb 2026
Viewed by 442
Abstract
Colibactin, a genotoxin produced by pks+ E. coli, imprints highly specific mutational signatures SBS88 and ID18 in colorectal cancer (CRC) and even in normal colonic crypts. Population-scale analyses show these signatures are enriched in early-onset CRC, vary geographically, and are [...] Read more.
Colibactin, a genotoxin produced by pks+ E. coli, imprints highly specific mutational signatures SBS88 and ID18 in colorectal cancer (CRC) and even in normal colonic crypts. Population-scale analyses show these signatures are enriched in early-onset CRC, vary geographically, and are imprinted early during tumor evolution, where probabilistic attribution indicates that colibactin contributes to a measurable fraction of APC driver mutations in colibactin-positive cancers. Beyond colibactin, Fusobacterium nucleatum exerts clade-specific effects on tumor ecology and therapy response, with data supporting both chemoresistance and sensitization to anti-PD-1 in microsatellite stable (MSS) CRC. This article covers mechanistic, genomic, and molecular epidemiology evidence, outlines analytic standards for signature detection (whole-genome sequencing (WGS)/whole-exome sequencing (WES), single-sample fitting, and limits at low mutation counts), and charts translational paths spanning noninvasive screening (stool metagenomics + mutational signatures in tissue/circulating tumor DNA (ctDNA)), risk stratification, and microbial-targeted interventions (antibiotics, phages, ClbP inhibitors). Framing microbiome–genome crosstalk as a tractable axis enables testable clinical hypotheses for precision oncology. Full article
(This article belongs to the Special Issue Cancer Genomics, 2nd Edition)
Show Figures

Figure 1

Back to TopTop